UT3 The EuroQoL EQ-5D: An Outcome Measure for Use in Clinical And Economic Evaluation  by Kind, P & Charro de, F
Abstracts
UTILITIES METHODOLOGY ISSUES
U'I'I
TRADE-OFF PREFERENCES FOR
PHARMACEUTICAL DEVELOPMENT,
MARKETING, AND OUTCOMES EVALUATION
Johnson FR, Desvousges WH
Triangle Economic Research, Durham, NC, USA
In this workshop the presenters discuss limitations of
standard QAL Y estimates for evaluating health-care
treatments and outcomes. As a solution, they demon-
strate developing, administering, analyzing, and applying
a recent stated-preference (SP) or conjoint-analysis health
survey. The authors are among a small group of heath
economists who recently have begun to employ this ap-
proach to elicit preferences for risk-benefit trade-offs,
public-health benefits of reduced pollution exposures,
benefits of increased longevity, and quality-of-life differ-
entials among various cardio-pulmonary symptoms. SP
encompasses a variety of multiattribute preference-elicita-
tion survey techniques widely used by market researchers
to evaluate potential new products and new markets for
existing products. The SP technique is based on the prin-
ciple that products are composed of various attributes or
features. SP allows respondents to systematically rate,
rank, or choose trade-offs among attributes using a frac-
tional-factorial experimental design. The attributes of
these health outcomes may include symptoms, daily ac-
tivities, number of episodes, and costs or adverse side ef-
fects associated with treatment alternatives. Respondents'
trade-offs among outcomes, treatments, or other health-
care options indicate the relative importance of various
attributes. The workshop will help participants to iden-
tify salient attributes for pharmacoeconomic decisions
and to construct appropriate experimental designs. Ad-
ministration of a computerized survey also will be dem-
onstrated. The presenters will show how responses elic-
ited from this survey are employed to develop a measure
of health-state preferences. Such survey results are useful
for a wide variety of pharmaceutical and health-outcome
applications, including pharmaceutical development
strategies, formulary decisions, managed-care insurance
coverage, new drug market share forecasting, patient-sat-
isfaction assessment, information dissemination and la-
beling evaluation, public health policy analysis, and cost-
effectiveness comparisons across diverse outcomes.
U'I'2
PRACTICAL APPLICATIONS OF THE HEALTH
UTILITIES INDEX
Torrance GWI.2, Walker VI, Rosner AJ'
'Innovus Research Inc.,Burlington, Ontario, Canada; 2McMaster
University, Hamilton, Ontario, Canada
The Health Utilities Index is designed to describe and to
quantify the health status and the health-related quality-
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of-life (HRQOL) of subjects. This validated and reliable
instrument has been employed by over 100 research
groups worldwide and exists in three formats (face-to-
face interview, telephone interview and self-administra-
tion). Translations into several languages are also avail-
able. As a generic preference-weighted system, the Health
Utilities Index not only measures and describes health
status, but also provides a quantitative measure of
HRQOL as a single summary score based on community
preferences for health status. The score, founded on util-
ity theory and anchored to the conventional 0-1 (dead-
healthy) scale, is appropriate as a quality-weight in the
calculation of quality-adjusted life-years (QALYs). Given
that QALYs have been recognized as a universal measure
for use in cost-effectiveness/cost-utility analyses and are
recommended in the reporting and monitoring of popula-
tion health, this instrument has wide ranging applications
in outcomes and health economic research. This work-
shop will provide an introduction to the Health Utilities
Index and focus on its practical application. We will de-
scribe our experiences as they relate to issues such as fre-
quency and mode of administration, patient recall, com-
pliance, sample size considerations, data analysis and
interpretation. Citing previous studies, this workshop
will demonstrate how the Health Utilities Index can be
utilized in prospective clinical research, patient surveys
and as a means for developing utility estimates in retro-
spective health economic models. Researchers and ana-
lysts involved in quality-of-life and health economic eval-
uations will gain a working knowledge of the Health
Utilities Index and an appreciation of its diversified use as
a generic HRQOL instrument.
U'I'iI
THE EuroQoL EQ-SD: AN OUTCOME MEASURE
FOR USE IN CLINICAL AND ECONOMIC
EVALUATION
Kind pi, de Charro P
'Centre for Health Economics, University of York, York, UK;
2Centre for Health Policy and Law, Erasmus University,
Rotterdam, The Netherlands
The measurement of health outcomes is central to all
evaluative studies. Clinical practice too is shaped by the
need to monitor health status, and changes in health sta-
tus. A prime requirement in most studies is the capacity
to represent benefits (or disbenefits) in terms of a single,
aggregate value. This property is typically absent from
profile measures that characterise health status in terms
of separate dimension scores. EQ-5D is a generic measure
that yields a single index value for health status based on
self-reported problems on each of 5 dimensions-mobility,
self care, usual activity, pain/discomfort, anxiety/depres-
sion. Utility weights for each of 245 health states are
available. EQ-5D is one of a handful of measures recom-
mended by the Washington Panel on Cost-Effectiveness.
Elsewhere EQ-5D has received official sanction under the
European Commission BIOMED programme and has
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been incorporated in the English National Health Survey.
EQ-5D has rapidly been assimilated into clinical trials by
many of the major pharmaceuticals. This workshop is de-
signed to provide an overview of the development of EQ-
5D, outlining the research programme undertaken by the
EuroQoL Group over the past 10 years; to report on its
use in clinical and economic evaluation; and to detail its
international take-up. It is expected that workshop at-
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tendees will be primarily researchers and analysts con-
cerned with clinical and economic evaluation, particu-
larly where international collaboration is involved. Thus
far EQ-5D has been translated into more than 25 lan-
guages. Participation in the Workshop should provide
sufficient exposure to enable all attendees to reach a bal-
anced conclusion regarding the usefulness of EQ-5D.
